August 12, 2020 — Random Walk Imaging AB (RWI), a company developing novel software solutions for diffusion magnetic resonance imaging (MRI), announced the launch of its first commercial software product for clinical researchers and radiologists. The dVIEWR Powered by MICE Toolkit is the result of a collaboration with NONPI Medical AB, with whom RWI has entered into an exclusive license and development agreement to market dVIEWR worldwide. RWI is hosting a booth at the first virtual International Society for Magnetic Resonance in Medicine Conference & Exhibition, August 8-14, 2020, with a demonstration of dVIEWRavailable at www.dviewr.com.
dVIEWR provides novel parameter maps that offer actionable information on tissue microstructure at an unprecedented level of detail and precision. By powering the software through MICE Toolkit, the ‘drag and drop’ interface allows clinical researchers without extensive programming experience to run custom image analysis workflows, quickly and easily. Similarly, the interface also benefits more experienced users to customize their own workflow designs, inputs and outputs.
“The value that this level of detail and precision in diffusion MRI offers has most recently been shown in a multiple sclerosis study published in Brain Communications. In the study, the unique parameters acquired using RWI’s advanced protocols could be correlated to clinical scores, which had not been seen with conventional methods such as diffusion tensor imaging,” said Peter Hoffmann-Fischer of Random Walk Imaging. “With dVIEWR, we have now made it even easier for researchers to incorporate these workflows and obtain novel contrasts for further analysis or formal presentation.”
“By integrating MICE Toolkit with the proprietary protocol algorithms from RWI, dVIEWR Powered by MICE Toolkit becomes a truly interdisciplinary software that provides a unique toolkit of functionality, accessible to everyone in the field of diffusion MRI,” said Simon Lindgren of NONPI Medical.
For more information: www.rwi.se
May 03, 2024 
